Cantor Fitzgerald Reinstates Overweight on ALX Oncology Holdings, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Alethia Young has reinstated ALX Oncology Holdings (NASDAQ:ALXO) with an Overweight rating and maintained a price target of $18.
September 07, 2023 | 2:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ALX Oncology Holdings has been reinstated with an Overweight rating by Cantor Fitzgerald, with a maintained price target of $18.
The reinstatement of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for ALX Oncology Holdings. The maintained price target of $18 also suggests that the analyst believes the stock is undervalued at current prices, which could lead to upward pressure on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100